CRVO -
CervoMed Inc. Common Stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 9.04 -0.22 (-2.49%) |
--- |
-0.04 (-0.45%) |
-0.09 (-1.01%) |
--- |
-0.22 (-2.49%) |
-0.22 (-2.37%) |
-0.22 (-2.37%) |
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Earnings & Ratios
- Basic EPS:
- -0.7
- Diluted EPS:
- Basic P/E:
- -12.5929
- Diluted P/E:
- RSI(14) 1m:
- 26.64
- VWAP:
- 8.82
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Dec 04, 2025 22:00
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
Dec 02, 2025 12:00
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 24, 2025 12:00
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Oct 22, 2025 11:00
CervoMed to Present at the Emerging Growth Conference
Oct 20, 2025 12:00
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Oct 02, 2025 12:00
CervoMed to Participate in Upcoming Investor Conferences
Sep 03, 2025 12:00
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Jul 28, 2025 11:00
CervoMed to Present at the 8th International Lewy Body Dementia Conference
Jan 29, 2025 13:00
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Oct 02, 2024 12:00